Alpha Capital Management’s ResMed RMD Stock Holding History

Alpha Capital Management’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-34,739	Closed	-$2.71M	–	96
2017 Q2	$2.71M	Sell	34,739 -903	-3%	-$64.6K	1.34%	11
2017 Q1	$2.56M	Buy	35,642 +1,596	+5%	+$110K	1.79%	10
2016 Q4	$2.11M	Sell	34,046 -128	-0.4%	-$7.84K	1.45%	26
2016 Q3	$2.21M	Buy	+34,174	New	+$2.27M	1.61%	27

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

CBOA

Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alpha Capital Management's RMD Position: Q3 2017 in Review

Alpha Capital Management sold out of ResMed (RMD) in Q3 2017, closing a stake of 34,739 shares — an estimated $2.71M sold.

Alpha Capital Management first reported a position in RMD in Q3 2016 and held it in 4 quarters. The position peaked at $2.71M in Q2 2017. 362 funds tracked by Wall St. Rank hold RMD as of Q3 2017.

Alpha Capital Management reported no remaining ResMed position as of Q3 2017 after selling out during the quarter.
Alpha Capital Management sold 34,739 ResMed shares in Q3 2017, an estimated $2.71M.
Alpha Capital Management first reported a position in ResMed in Q3 2016 and held it in 4 quarters.
Alpha Capital Management's ResMed position peaked at $2.71M in Q2 2017.
362 funds tracked by Wall St. Rank held ResMed as of Q3 2017.

Based on Alpha Capital Management's 13F filing for Q3 2017, filed 13 Oct 2017.